Quinine poisoning is rare but serious. Attempts at treatment by active removal have proved unsuccessful because of its high degree of protein binding. We describe two cases of non-accidental overdose of quinine (19.5 g and 15 g) with potentially fatal serum quinine levels. Both patients were treated by 2 periods of charcoal haemoperfusion during which quinine clearances of up to 125 ml/min were obtained. Both patients recovered, though one had some residual visual disturbance. We suggest that in cases of quinine poisoning, charcoal haemoperfusion may be a safe and effective method of drug removal, to be used with stellate ganglion block.
Introduction
Quinine poisoning is uncommon, but the results are often serious with a fatal or disabling outcome. The most characteristic abnormality is a toxic amblyopia which is often permanent but has been treated successfully with stellate ganglion block. Haemoperfusion over charcoal or resin has been used effectively to treat various poisonings. This is the first report to describe the clinical use of charcoal haemoperfusion in the removal of quinine, a drug which is highly protein-bound and has hitherto resisted active removal by other means.
Method
The serum quinine estimations were made with a devised assay of ultraviolet absorption after chloroform extraction. Standard or blank (1 ml) was mixed with I ml of 5 M sodium hydroxide and the quinine sulphate extracted into 10 ml of chloroform. After mixing and centrifuging, the aqueous layer was discarded and the chloroform layer filtered and acidified with 0-25 M sulphuric acid. The ultraviolet absorbance was then measured at 250 nm. A graph was constructed, plotting absorbance against concentration of standards (5, 10, 20, 30 
Discussion
The medicinal use of quinine is currently limited to the treatment of malaria and the doubtful prevention of night cramps. As oral quinine sulphate, it is 95% absorbed from the small intestine, with peak blood levels occurring 1-3 hr after a therapeutic dose. It is 70% protein-bound and mainly distributed in the extracellular fluid. Hepatic hydroxylation of available quinine occurs rapidly and excretion is mainly in the urine, being twice as great when the urine is acidic (Goodman and Gilman, 1975; Taggart et al., 1948) . The fatal dose is approximately 8 g, but the range is wide with reports of a fatality after 3 g (Markham, Dodson and Eckberg, 1967) , and survival after 31 g (Glick and Mumford, 1955) . Specific measures for the active treatment of quinine poisoning have included forced acid diuresis, peritoneal dialysis (Donadio, 1968) , haemodialysis (Floyd et al., 1974) and exchange transfusion (Burrows et al., 1972) : all with only limited success. The clearance of quinine during haemodialysis is 35 ml/min and during peritoneal dialysis only 8-13 ml/min, which is less than the urinary clearance under optimum conditions (135-18 ml/min). The failure of these membrane dependent systems to remove the drug is H, v the result of its high affinity for plasma bindingproteins. Laboratory studies have indicated that quinine is likely to be removed by charcoal haemoperfusion (Kolthammer, 1975) and we now confirm this in the clinical situation.
The toxic effects of quinine are related to the circulating level of the free drug. It is believed that the quinine estimation used has a tendency to overestimate, but the early serum levels were very high (17-31 mg/litre), well in excess of levels in previously reported fatal cases (Coutselinis and Boukis, 1977) . In the first case, the obvious clinical improvement was not maintained and high levels were again reached 36 hr after the first treatment. After the second haemoperfusion, the concentrations remained acceptably low and declined steadily. Case 2 also showed clinical improvement after the first haemoperfusion, with a more rapid rise in levels at the end of treatment.
The total amount of quinine recovered during haemoperfusion cannot have been substantial. The most optimistic calculation of the quantity of quinine adsorbed during a haemoperfusion amounts to the equivalent of only 3 tablets. However, this does not deny that haemoperfusion has no clinical benefit since lowering the serum concentration certainly alleviated the symptoms. In retrospect, it would have been better to have continued with this therapy for a much longer period with a view to sparing the target organs until the liver and kidneys had reduced the body load to safe levels.
The rebound rise in drug levels following haemoperfusion is seen in other poisonings, particularly glutethimide (Vale et al., 1975) . It is the result of redistribution throughout the extracellular compartment and in our cases also probably as a result of continued gastro-intestinal absorption. The quinine clearances we obtained by charcoal haemoperfusion (105-125 ml/min) compare favourably with in vitro studies and are considerably better than results obtained by other methods of active quinine removal. We therefore suggest that in quinine poisoning with high serum levels, active removal of the drug by charcoal column haemoperfusion should be considered in anticipation of symptoms.
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